M&A Deal Summary |
|
---|---|
Date | 2013-09-04 |
Target | Rochester Medical |
Sector | Medical Products |
Buyer(s) | C. R. Bard |
Deal Type | Add-on Acquisition |
Deal Value | 262M USD |
Advisor(s) | Piper Sandler & Co. (Financial) Dorsey & Whitney (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1907 |
Sector | Medical Products |
Employees | 14,900 |
Revenue | 3.7B USD (2016) |
C. R. Bard, Inc. is a multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology, and surgical specialties. C. R. Bard was formed in 1907 and is based in Murray Hill, New Jersey.
DEAL STATS | # |
---|---|
Overall | 21 of 23 |
Sector (Medical Products) | 17 of 18 |
Type (Add-on Acquisition) | 20 of 22 |
State (Minnesota) | 3 of 3 |
Country (United States) | 20 of 22 |
Year (2013) | 2 of 3 |
Size (of disclosed) | 1 of 14 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-08-19 |
Medafor
Minneapolis, Minnesota, United States Medafor, Inc., is a developer and supplier of plant based hemostatic agents. Medafor develop and market its unique, patented hemostatic technology based on engineered biopolymeric microporous particles. |
Buy | $200M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-10-23 |
NeoMend
Irvine, California, United States NeoMend, Inc., is a developer and supplier of sprayable surgical sealants and anti-adhesion products. An innovator in sealant and adhesion-prevention products for the surgical marketplace focused on the design, development and commercialization of innovative surgical sealants and adhesion prevention products derived from the Progel® technology platform. |
Buy | $140M |